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BACKGROUND. Molecular stratification of prostate cancer (PCa) based on genetic aberrations
including ETS or RAF gene-rearrangements, PTEN deletion, and SPINK1 over-expression show
clear prognostic and diagnostic utility. Gene rearrangements involving ETS transcription factors
are frequent pathogenetic somatic events observed in PCa. Incidence of ETS rearrangements in
Caucasian PCa patients has been reported, however, occurrence in Indian population is largely
unknown. The aim of this study was to determine the prevalence of the ETS and RAF kinase
gene rearrangements, SPINK1 over-expression, and PTEN deletion in this cohort.
METHODS. In this multi-center study, formalin-fixed paraffin embedded (FFPE) PCa
specimens (n¼ 121) were procured from four major medical institutions in India. The tissues
were sectioned and molecular profiling was done using immunohistochemistry (IHC), RNA
in situ hybridization (RNA-ISH) and/or fluorescence in situ hybridization (FISH).
RESULTS. ERG over-expression was detected in 48.9% (46/94) PCa specimens by IHC,
which was confirmed in a subset of cases by FISH. Among other ETS family members,
while ETV1 transcript was detected in one case by RNA-ISH, no alteration in ETV4 was
observed. SPINK1 over-expression was observed in 12.5% (12/96) and PTEN deletion in
21.52% (17/79) of the total PCa cases. Interestingly, PTEN deletion was found in 30% of the
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ERG-positive cases (P¼ 0.017) but in only one case with SPINK1 over-expression (P¼ 0.67).
BRAF and RAF1 gene rearrangements were detected in 1% and 4.5% of the PCa cases,
respectively.
CONCLUSIONS. This is the first report on comprehensive molecular profiling of the major
spectrum of the causal aberrations in Indianmenwith PCa. Our findings suggest that ETS gene
rearrangement and SPINK1 over-expression patterns in North Indian population largely
resembled those observed in Caucasian population but differed from Japanese andChinese PCa
patients. The molecular profiling data presented in this study could help in clinical decision-
making for the pursuit of surgery, diagnosis, and in selection of therapeutic intervention.
Prostate 75:1051–1062, 2015. # 2015 TheAuthors. The Prostate, published byWiley Periodicals, Inc.
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INTRODUCTION
Prostate cancer (PCa) is one of the most common
malignancies after lung cancer and the second most
common cause of cancer-related death among men
worldwide. The incidence of PCa in India has been
steadily increasing concomitant with an increase
in life expectancy. According to the National Cancer
Registry program by the Indian Council of Medical
Research, New Delhi, PCa is estimated to increase by
140% in the next few years [1,2]. The challenges posed
in diagnosing and treating prostate cancer is attrib-
uted to the clinical and molecular heterogeneity
associated with this disease. The seminal discovery of
the recurrent (>50%) genetic rearrangements involv-
ing the androgen-regulated gene transmembrane pro-
tease, serine 2 (TMPRSS2), with v-ets erythroblastosis
virus E26 oncogene homolog (avian) (ERG) in PCa
prompted the molecular categorization of PCa into
distinct molecular subtypes [3], similar to hematologic
malignancies, for identifying patients with aggressive
subtypes and distinct therapeutic targets. Subse-
quently, discovery of genetic rearrangements involv-
ing TMPRSS2 with other 3’ erythroblastosis virus E26
transformation-specific (ETS) transcription factor fam-
ily members such as ETV1 (5%), ETV4 (5%), or
ETV5 (1%) led to further classification of PCa.
In a separate study using Cancer Outlier Profile
Analysis (COPA), SPINK1 (serine peptidase inhibitor,
Kazal type 1) was shown to be over-expressed in
10–15% of the total PCa cases [4]. Interestingly,
SPINK1 and ETS over-expression demonstrated mutu-
ally exclusive pattern across multiple independent
PCa cohorts, and SPINK1 outlier expression was
associated with an aggressive subset of prostate
cancers [4–6].
Another important molecular event in PCa is the
inactivation of the phosphatase and tensin homolog
(PTEN) gene by genomic deletion or rearrangement,
including intragenic breakage and translocation. PTEN
deletion or rearrangement has been reported in 20–30%
of PCa and is also associated with aggressive
cancers [7–9]. Interestingly, mouse model of PCa
demonstrated that PTEN loss and ERG genetic rear-
rangement might cooperate in the development of
prostate adenocarcinoma [10,11]. Many independent
studies have shown that PTEN deletion and ERG
genetic alterations frequently coexist, and incidences of
PTEN deletions are more frequent in ETS fusion-
positive PCa than in fusion-negative cancers [7,8,12,13].
Using paired-end next-generation sequencing
approach, the druggable RAF kinase genetic rear-
rangements, SLC45A3-BRAF (solute carrier family 45,
member 3–v-raf murine sarcoma viral oncogene
homolog B1) and ESRP1-RAF1 (epithelial splicing
regulatory protein-1–v-raf-1murine leukemia viral
oncogene homolog-1) were discovered in 2% of the
PCa patients [14]. Most importantly, the RAF genetic
rearrangements demonstrated sensitivity to sorafenib,
a US Food and Drug Administration (FDA) approved
RAF/MEK inhibitor suggesting that RAF genetic
rearrangements, although rare, may benefit patients
positive for RAF rearrangements [14].
Although TMPRSS2-ERG gene fusion is one of the
highly recurrent (50%) oncogenic drivers in PCa, it
has been a challenging therapeutic target. A recent
study demonstrated a potential strategy to therapeuti-
cally target ERG via its interacting partner protein,
poly-ADP-ribose polymerase (PARP) for the treatment
of ERG fusion-positive PCa [15]. Interestingly, lower
incidence of ERG genetic rearrangement has been
reported in African Americans (28%) in compar-
ison to 50–60% recurrence in Caucasian Americans.
Moreover, incidence of PTEN deletion is low (7%) in
African American men compared to Caucasian men
and the prevalence of SPINK1 over-expression is
high (23%) among African American men com-
pared to their Caucasian counterpart [16]. Much
lower recurrence of ERG alteration (10–20%) has
been reported among the Japanese [17] and Chinese
PCa cohort [18] compared to the Western popula-
tion. Moreover, Filipinos with PCa are at increased
risk of progressing to advanced stages of PCa and
have lower survival rates compared to other Asians.
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Prevalence of TMPRSS2-ERG rearrangement is 23%
among Filipino PCa patients with an increased rate
(33%) observed in the advanced PCa cohort [19].
Comprehensive landscape of genetic alterations in
PCa patients from the Indian sub-continent is
currently lacking. Recently, a report on PCa patients
from India reported low recurrence (27%) of
TMPRSS2-ERG genetic rearrangement [20]. How-
ever, inherent limitations of this study include the
small cohort size (n¼ 30) and all samples analyzed
were from a single institution, thus extrapolation of
these results to broader population is difficult. Here,
to study the genetic heterogeneity of PCa in the
Indian population, we performed comprehensive
characterization of patient samples to determine the
prevalence of genetic rearrangements involving ETS
gene family members (ERG, ETV1, and ETV4); non-
ETS genetic rearrangements such as RAF kinase
family fusions (BRAF or RAF1), SPINK1 over-
expression and the status of the tumor suppressor
gene PTEN. Our data revealed that the ETS gene
rearrangement and SPINK1 over-expression patterns
in the North Indian population largely resembled
those observed in the Caucasian population but
differed from Japanese and Chinese PCa patients.
MATERIALS AND METHODS
Prostate Specimens
A total of 121PCa specimens (including five benign
prostate specimens) were procured from All India
Institute of Medical Sciences, New Delhi; King George’s
Medical University, Lucknow; Digdarshika Pathology
Laboratory, Lucknow; and GSVM Medical College,
Kanpur. A total of 22PCa specimens were excluded
from the study based on low tumor content and
integrity of the cancer tissues. All PCa specimens were
collected from patients with written informed consent
and upon Institutional Review Board approval. The
study PCa cohort included specimens from men who
underwent prostatectomy (n¼ 40), needle core biopsies
(n¼ 48), and transurethral resection of the prostate
(TURP) (n¼ 33) to relieve obstructive symptoms from
locally advanced disease at the participating institutions
between year 2010 and 2014. None of the patients
received preoperative radiation or androgen depriva-
tion therapy. All patients included in this study were of
Indian descent residing in northern India. All specimen
included in the study were de-identified.
ERG and SPINK1 Immunohistochemistry
Immunohistochemistry was performed on unstained
formalin-fixed, paraffin-embedded (FFPE) tissue sec-
tions obtained from the prostatectomy, needle core
biopsies, or TURP specimen blocks. Primary monoclo-
nal antibody against ERG, clone EPR 3864 (Epitomics,
Burlingame, CA) or monoclonal antibody against
SPINK1 (H00006690-M01-Abnova, Taiwan) was
used on the automated Ventana Benchmark staining
platform (Ventana Medical Systems-A Roche group,
Tucson, AZ). Staining of blood vessels was used as
a positive control and slides displaying no staining
of vessels were excluded from further analysis.
All IHC slides were evaluated by a board certified
pathologist (LPK).
Fluorescence In Situ Hybridization (FISH)
FISH assays were performed on unstained FFPE
sections obtained from the PCa specimen blocks. BAC
clones (ERG 5’-RP11-830D9; ERG 3’-RP11-143L14;
PTEN locus probe-RP11-165M8; chr10 control probe
RP11-351D16; ETV4 5’-RP11-147C10; ETV4 3’-
CTD3215I16; BRAF 5’-RP11-767F15; BRAF 3’-RP11-
248P7; RAF1 5’-RP11-767C1; RAF1 3’-RP11-586C12)
were selected from the UCSC genome browser and
purchased through BACPAC resources (Children’s
Hospital, Oakland, CA). Following colony purifica-
tion DNA was prepared using QiagenTips-100
(Qiagen, Valencia, CA). DNA was labeled by nick
translation method with biotin-16-dUTP and digox-
igenin-11-dUTP for 3’ and 5’ probes and PTEN locus
and CEN10 control probes respectively (Roche, USA).
Probe DNAwas precipitated and dissolved in hybrid-
ization mixture containing 50% formamide, 2X SSC,
10% dextran sulphate, and 1% Denhardt’s solution.
Approximately two hundred nanogram of labeled
probe was hybridized to normal human chromosomes
to confirm the map position of each BAC clone. FISH
signals were obtained using anti-digoxigenin-fluores-
cein and AlexaFluor-594 conjugate to obtain green
and red colors, respectively. Fluorescence images
were captured using a high resolution CCD camera
controlled by ISIS image processing software (Meta-
systems, Germany).
Deletion of PTEN was defined as fewer than two
copies of the gene specific probe in the presence of
two reference signals in >20% of the tumor nuclei.
For both ERG rearrangement and PTEN deletion, at
least one hundred tumor nuclei per case were eval-
uated under a fluorescence microscope (Carl Zeiss &
Metasystems, Germany).
RNA In Situ Hybridization and Evaluation Criteria
RNA in situ hybridization (RNA-ISH) was per-
formed as described previously using RNAscope
FFPE Reagent Kit 2.0 (Advanced Cell Diagnostics,
Hayward, CA) [21]. Briefly, FFPE sections were baked
Molecular Profiling of ETS and Non-ETS Aberrations 1053
The Prostate
at 60 °C for 1 hr. ETV1 RNA probe (ETV1 Accession
Number NM_004956.4, region 998-2031) and POLR2A
(as a positive control) were designed by Advanced
Cell Diagnostics (Hayward, CA). Tissues were depar-
affinized in xylene twice for 15min each with periodic
agitation, slides were then immersed in 100% ethanol
twice for 3min each with periodic agitation and air-
dried for 5min. Tissues were circled using a pap pen
(Vector, H-4000), allowed to dry and treated with
pretreatment 1 buffer for 10min. The slides were
processed using previously established protocol [21]
and mounted in Cytoseal XYL (Thermo Scientific,
#8312-4) for viewing under bright-field microscope.
Positive controls were performed for all runs using a
POLR2A gene-specific RNA probe.
RNA-ISH expression intensity scoring guidelines
were established to classify tumor foci as ETV1
positive or ETV1 negative [22]. ETV1 expression by
RNA-ISH appeared as distinct cytoplasmic punctate
dots. All tumor foci were evaluated and scanned at
20 magnification. Scoring for an entire tumor focus
was based on the highest ETV1 intensity using criteria
previously reported [21]. All ETV1 RNA-ISH slides
were reviewed by study pathologist (LPK).
Statistical Analysis
Fisher’s exact tests were used to evaluate associa-
tion between categorical variables. For analyzing the
association between PTEN deletion status (response,
normal vs. deletion) with co-occurrence of ERG or
SPINK1 positive status logistic regression has been
applied. For assessing any association between ERG
positive, SPINK1 positive, or SPINK1 negative sta-
tuses and Gleason score (using numeric Gleason score
as a response) linear regression model was used. For
all statistical tests, a P< 0.05 was considered statisti-
cally significant.
RESULTS
Prevalence of ERG, ETV1, and
ETV4 Genetic Rearrangements
ERG oncoprotein expression was evaluated by IHC
on 94 PCa biopsies and five benign prostate speci-
mens. A total of 46 out of 94 PCa (48.9%) were found
to be positive for ERG expression (Fig. 1A) and all
five benign PCa specimens were negative for ERG
over-expression. We next confirmed ERG gene rear-
rangement in a subset of patients (n¼ 17) that were
positive for ERG staining by FISH. As anticipated, all
cases showed ERG rearrangement either by ERG split
signal or 5’ deletion of ERG (Fig. 1A, bottom panel).
Results from the FISH assay of ERG rearrangement-
positive cases revealed that ERG gene fusion occurred
in neoplastic cells but not in adjacent benign nuclei or
stromal cells. The majority of the cases included in
this study had index tumor Gleason scores of 7 or
higher (82/94, 87%) and all available clinical informa-
tion associated with the patients’ specimens are
listed in Supplementary Table 1. For the remaining 43
ERG-negative cases, ETV1, and ETV4 rearrangement
detection was performed by RNA-ISH and FISH,
respectively. None of the 43 (0/43) PCa specimens
tested by ETV4 break-apart FISH were positive and
only one PCa specimen was detected as ETV1 positive
as evaluated by RNA-ISH (Fig. 1B). Of note, the
ETV1-positive case was negative for ERG and SPINK1
over-expression by IHC. None of the benign speci-
mens (n¼ 5) were positive for ERG, ETV1, or ETV4
genetic rearrangements.
Prevalence of SPINK1 Over-Expression
SPINK1 over-expression was evaluated by per-
forming IHC on all the ERG-negative cases and the
cases where the ERG-positive immunostaining was
heterogeneous (7 cases). A total of 66 PCa specimens
were immunostained for the SPINK1 over-expression,
12 cases were confirmed as SPINK1-positive repre-
senting 12.76% of the 94 total PCa specimens
(Fig. 2A–D). Importantly, none of the SPINK1-positive
cases were ERG rearrangement-positive, confirming
mutual exclusivity of both genetic alterations. More-
over, all seven ERG-positive heterogeneous cases
were found to be negative for SPINK1. Of note,
SPINK1 prevalence in our cohort is similar to
the SPINK1 incidence (10–15%) reported in the
Caucasian cohorts [4,5]. As anticipated none of the
benign specimen (n¼ 5) were positive for SPINK1
over-expression. No significant association between
ERG positive status and Gleason score was found
when adjusted for SPINK1 status (P¼ 0.42) using a
linear model (numeric Gleason scores) and an ordinal
proportional odds regression with fine ordinal catego-
rization of Gleason scoring (<6, 3þ 4, 4þ 3, 8–10).
Although SPINK1 negative cases showed a trend for
increased Gleason score (0.58, SE¼ 0.29, P¼ 0.053)
using a linear regression model. The effect reached
significance in the ordinal model with the cumulative
logOR of 1.26 (SE¼ 0.64, P¼ 0.049).
Concomitant Presence of ERG Rearrangement,
SPINK1 Over-Expression, and PTEN Deletion
To assess PTEN genomic deletion, a two color
interphase FISH approach was used as PTEN dele-
tions are interstitial and are usually limited to small
regions of chromosome 10. The PTEN FISH was
performed on 92 PCa specimens, of those 13 speci-
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Fig. 1. IHC staining and FISH for ERG rearrangement and RNA-ISH for ETV1. Panel A, whole section view of a prostate carcinoma
tissue (Gleason score 3þ 3) showing ERG expression by IHC staining (panel on left). Right panel showing IHC staining for ERG over-
expression (20 magnification) with the corresponding H&E stained sections (top). Bottom panel shows FISH for ERG genetic
rearrangement using ERG break-apart probes. Yellow arrow shows rearranged ERG, and co-localizing red-green signal depicts intact ERG
locus. Panel B shows ETV1 expression by RNA-ISH with a maximum intensity score 4 (20 magnification).
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mens were excluded from the analysis due to no
signal or no hybridization on the tissue sections.
Homozygous deletion of PTEN was observed in
11.39% (9 out of 79) of the PCa cases whereas hemi-
zygous deletion was observed in 10.13% (8 out of 79)
of the PCa cases (Fig. 3A–C). We also observed
aneuploidy (>2 copies of PTEN) in 17.72% (14 out of
79) of the PCa cases (Fig. 3A–B). Interestingly, 30% (14
out of 46) of the ERG-positive cases showed PTEN
deletion compared to only one SPINK1-positive case
(1 out of 12) with PTEN deletion. Logistic regression
was applied to model the association of the PTEN
deletion status (response, normal vs. deletion) with
ERG and SPINK1 positive status. ERG positivity leads
to an increase in the chances to develop a PTEN
deletion of 1.65 on the logit scale (SE¼ 0.69,
P¼ 0.017). Conversely, the association of SPINK1
positive status with PTEN deletion was non-
significant (P¼ 0.67), and point estimate of the effect
was much smaller (0.64 on logit scale, SE¼ 1.47).
Thus, our findings corroborate with the previous
studies demonstrating a significant overlap between
ERG genetic rearrangements and PTEN deletions
[12,23]. Moreover, the incidence of ERG positivity in
patients with PTEN deletions was 0.82, exact 95%
Confidence Interval (CI) (0.59, 0.94). Likewise the
incidence of SPINK1 positive status with PTEN
deletion was much smaller, 0.33, exact 95% CI (0.008,
0.91), although the sample size for the latter is too
small to be interpreted.
Incidence of BRAF and RAF1 Rearrangements
BRAF and RAF1 rearrangements were detected by
FISH using break-apart probes on 88 and 63 PCa
specimens, respectively. Interestingly, one out of 88
(1%) PCa cases harbored BRAF genetic rearrange-
ment and two cases displayed focal amplification
with 5–7 copies of BRAF (Fig. 4A). These results are
consistent with our previous finding that reported
2% incidence of BRAF rearrangement in prostate
cancer [14]. RAF1 rearrangement was observed in
4.5% (3 out of 66) of PCa cases; PCA-23 harbored
RAF1 rearrangement, second case (PCA-56) dis-
played 3’ deletion and third case (PCA-40) displayed
3’ deletion in one tumor foci and RAF amplification
and 5’ deletion in another tumor foci (Fig. 4B, top
panel). We also observed a single case (PCA-16) with
4 copies of RAF1 resulting from aneuploidy (Fig. 4B,
bottom panel). Notably, all the cases that were
positive for rearrangements or amplification of BRAF
or RAF1 had features of advanced PCa including high
Gleason score (four cases with Gleason score 9 and
two cases with Gleason score 7). Intriguingly, all the
Fig. 2. IHC staining for SPINK1. Panel A and B show a prostatic adenocarcinoma with SPINK1 positive immunostaining with
the corresponding H&E stained section; Gleason score 3þ 4 (20 magnification). Panel C and D show a needle core biopsy
which demonstrates SPINK1 positive immunostaining with the corresponding H&E stained section; Gleason score 3þ 3 (4 and 
10 magnification in inset).
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Fig. 3. FISH for PTEN aberrations. Panel A, schematic diagram showing the genomic organization of PTEN gene on Chr10 q23.3 and
chromosome 10 control probe (q11.12). Green and red bars indicate the chromosome 10 control probe and PTEN BAC clones,
respectively. FISH images of the PCa specimens, PCA-87 shows normal PTEN copy number with two red and two green signals
corresponding to PTEN and Chr10 control probe, respectively. PCA-74 shows heterozygous deletion of PTEN showing loss of one red
signal, but two green centromere signals. PCA-77 depicts homozygous deletion of PTEN (loss of red signals), but two green centromere
signals. PCA-78 shows aneuploidy with 3-4 copies of chromosome 10 and PTEN. Panel B, percent distribution of the PTEN aberrations.
Panel C shows ERG genetic rearrangement using ERG break-apart probes and homozygous deletion of PTEN in the same patient (PCA-61).
Likewise, PCA-70 shows ERG genetic rearrangement and normal PTEN status.
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Fig. 4. FISH for RAF genetic rearrangements. Panel A, schematic diagram showing the genomic organization of BRAF gene on chr7q34.
Green and red bars indicate the 5’ and 3’ BAC clones, respectively. FISH images of the PCa specimens (PCA-73 & 25) show BRAF
amplification (left) and BRAF rearrangement (middle) in PCA-77 (right). Panel B, schematic diagram showing the genomic organization of
the RAF1 gene on chr3p25. Green and red bars indicate 5’ and 3’ BAC clones, respectively. FISH images of the PCa specimens (PCA-40)
show RAF1 rearrangement with 5’ deletion (green signal missing), 3’ deletion (red signaling missing), and 5’ deletion with 3 copies of normal
RAF1 in the top panel. Likewise, PCa specimens PCA-23, PCA-16, and PCA-56 show RAF rearrangement, amplification, and 3’ deletion,
respectively (bottom panel).
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RAF rearrangement-positive cases were also positive
for ERG rearrangement, but not the sample harboring
BRAF amplification.
DISCUSSION
In this study, we stratified Indian PCa cohort
based on the molecular alterations known to be
prevalent among different PCa populations in the
world [3,4,24–27]. To our knowledge, this is the first
study to comprehensively evaluate the entire spec-
trum of driving aberrations in Indian PCa samples
that include ERG, ETV1, ETV4, RAF kinase genetic
rearrangements, SPINK1 over-expression, and PTEN
deletion. Our findings indicate a higher incidence
of ERG rearrangement (49%) in the Indian PCa
cohort compared to a recent report by Rawal and
colleagues (27%) [20]. This discrepancy could arise
from the smaller cohort size (total 30 PCa cases)
and the samples collected from a single medical
institution. Additionally, they characterized only the
ERG gene rearrangement using a different ERG
antibody (9FY clone, Biocare Medical Inc.) [20] for
IHC analysis as well as variation in evaluation
criteria, and possibly therapeutic interventions
(anti-androgen therapy). Most importantly, Park
et al., demonstrated that ERG immunostaining using
same monoclonal antibody that we have used
against ERG had an overall 95.7% sensitivity and
96.5% specificity for ERG rearrangements, suggest-
ing that ERG expression by IHC has high concord-
ance with FISH [28].
Although, ETS genetic rearrangement represents a
highly prevalent genetic alteration (50–60%) among
PCa patients of the Western world, therapeutic target-
ing of ETS transcription remains a challenge. Never-
theless, we have shown that ERG interacts with the
enzyme poly (ADP-ribose) polymerase 1 (PARP1) in a
DNA-independent manner and pharmacological
inhibition of PARP1 inhibits ETS-positive PCa xeno-
graft [15]. Our findings also showed that ETV1
genetic rearrangements are less recurrent (1%) in
Indian PCa cohort than what has been reported in the
Caucasian cohorts (5%) [24,29], although studies
with larger patient cohorts are needed to validate our
finding. Interestingly, Baena et al., demonstrated that
ERG and ETV1 regulates androgen receptor (AR)
target genes inversely, ERG negatively regulates the
AR transcriptional program whereas ETV1 enhances
AR signaling and activation of the AR transcriptional
program [30]. Our data corroborates previous find-
ings that ERG rearrangements are clonal in nature as
all cells in a given cancer foci were positive for the
ERG expression, while distinct cancer foci in a single
prostate may have differing ERG rearrangement
status [12,31–33]. However recently, existence of rare
molecular subsets of PCa with dual gene rearrange-
ments, such as ERG/SPINK1 [34], ERG/ETV1, and
ERG/ETV4 in different tumor focus of the same
tumor has been noted [22].
Similar to the incidences reported in Caucasian
PCa cohorts [4,5], we also identified SPINK1 over-
expression in 12% of the PCa cases in Indian
subcontinent. A recent report on African American
men (n¼ 105) with PCa showed higher SPINK1
incidence (23.8%) compared to only 8% SPINK1-
positive cases in Caucasian PCa samples
(n¼ 113) [16], highlighting differences at the molec-
ular level in these two clinicopathologically matched
PCa cohorts and racial disparities in prostate can-
cer [35–37]. Several independent studies have con-
firmed the mutual exclusivity of SPINK1 and ERG
rearrangements in PCa [4]. SPINK1 over-expression is
associated with aggressive phenotype among ETS-
negative PCa cases, with higher risk of biochemical
recurrence than SPINK1-negative patients [4,5]. Pre-
viously, we showed that SPINK1 interacts with
epidermal growth factor receptor (EGFR) and acti-
vates downstream signaling and EGFR dimeriza-
tion [38]. Moreover, monoclonal antibodies to either
SPINK1 or EGFR (cetuximab) significantly slowed
down tumor growth in SPINK1-positive tumor xeno-
grafted mice [38]. Of note, multiplex assay of SPINK1
and TMPRSS2-ERG along with GOLPH2 and PCA3
transcript expression could be utilized as predictors of
PCa, and most importantly these biomarkers could
outperform serum PSA or PCA3 alone in detecting the
disease [39].
Deletions or mutations in PTEN, which encodes a
phosphoinositide 3-phosphatase, have been found to
be associated with higher Gleason score, metastasis,
hormone resistance, and an overall poor progno-
sis [9,26,40]. Furthermore, the clinical significance of
molecular aberrations in PTEN, TMPRSS2-ERG, and
SPINK1 has been demonstrated in the development
of castration-resistant prostate cancer (CRPC) [23].
Here, we found almost equal proportion of homozy-
gous (11.39%) and heterozygous PTEN deletions
(10.13%) in the Indian PCa cohort. A recent report
demonstrated that heterozygous PTEN deletions are
less frequent in African American PCa cohort (6.9%)
than in Caucasian PCa cohort (19.8%) [16]. Moreover,
homozygous PTEN deletions are more prevalent
in CRPC whereas PTEN heterozygous deletions
occurred at higher frequency in localized PCa [6,23].
Importantly, loss of PTEN results in increased AKT
and mTOR signaling, suggesting that alterations in
the mTOR/AKT pathways could also be therapeuti-
cally targeted in patients harboring PTEN loss.
Indeed, a recent study demonstrated promising ther-
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apeutic outcomes upon dual inhibition of AKT and
mTORC1 in the preclinical genetically-engineered
mouse (GEM) model of CRPC [41].
In the present study, we found 4.5% (3 out of
66) RAF1 genetic rearrangements and 1% (1 out of
88) BRAF genetic rearrangement in the Indian PCa
cohort. Likewise, lower incidence of the BRAF
(2.5%) and RAF1 (1.5%) aberrations has been
reported in the Chinese PCa cohort as well [42].
Nevertheless, a high incidence of BRAF (29%) and
RAF1 (15%) copy number gain was observed in the
same cohort, suggesting activation of the RAS/
RAF/MEK/ERK signaling pathway [42]. In contrast
to Chinese PCa cohort, we found only one case
with BRAF focal amplification; however more stud-
ies with larger cohort size are needed to confirm
our finding. One of the limitations of our study is
the lack of patients’ follow-up information and the
evaluation of associations with clinical outcome, as
follow-up of the cancer patients is poor in India
due to inadequate health/medical awareness and
socioeconomic status of the patients. Nevertheless,
the current study provides an initial molecular
stratification of the PCa in this patient population
that could aid in clinical decision-making for the
pursuit of surgical, targeted therapy, hormonal
and/or chemo, and radiation therapy. Moreover, in
the current genomic and precision therapy era,
the diagnosis and treatment of PCa is rapidly
evolving [43,44]. Hence, comprehensive molecular
characterization of PCa patients from Indian sub-
continent utilizing high-throughput sequencing
approaches will inform the pursuit of appropriate
targeted therapies.
In summary, this is the first comprehensive report
demonstrating the prevalence of the ETS gene-
rearrangements, SPINK1 over-expression, druggable
RAF rearrangements and PTEN aberrations preva-
lent among Indian men with PCa. Taken together,
Indian PCa population characterized in this study
largely resembled the ETS gene rearrangement and
SPINK1 over-expression scenario observed in the
Caucasian race, and differed from the prevalence
reported in Japanese and Chinese patients; suggest-
ing racial disparity and differences at the molecular
level in prostate cancer. Most importantly, similar to
ALK gene fusions (5% of the cases) in non-small
cell lung cancer patients, who benefit from ALK
kinase inhibitors; the higher incidence of RAF
rearrangements positive PCa patients (5% in
Indian PCa) reported in this study may respond to
the FDA-approved RAF inhibitors or MEK inhibi-
tors. Therefore, understanding the underlying com-
mon molecular driver alterations prevalent among
Indian PCa patients will permit optimization of the
screening methods and selection of the appropriate
treatment regimen in this population.
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